Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. The efficacy and safety of tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, in patients with MASH and moderate or severe fibrosis is unclear. METHODS: We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks. The primary end point was resolution of MASH without worsening of fibrosis at 52 weeks. A key secondary end point was an improvement (decrease) of at least one fibrosis stage without worsening of MASH. RESULTS: Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group. The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons). The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42). The most common adverse events in the tirzepatide groups were gastrointestinal events, and most were mild or moderate in severity. CONCLUSIONS: In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis. Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH. (Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, NCT04166773.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome for all three studies was resolution of fatty liver disease without worsening of fibrosis, and significant improvements were noted.”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [83]
In the citing paper
“tirzepatide led to an increased proportion of participants reaching an improvement in fibrosis by at least one stage.83”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [83]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [29]
In the citing paper
“Other recent analyses have revealed survodutide, tirzepatide, and retatrutide to each significantly reduce liver fat with no evidence of worsening in markers of liver fibrosis.77, 78, 79”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [79]
In the citing paper
“tirzepatide also increased the proportion of patients achieving at least one-stage fibrosis improvement without MASH worsening (approximately 51–55% vs. 30% with placebo).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [224]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationVilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 301–400 of 999
Volčanšek, Š., Janež, A., Rizzo, M., & Muzurović, E. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108875 · Cited by 7
Woodard, J. S., Velji-Ibrahim, J., & Abrams, G. A. (2024) · Diseases · doi:10.3390/diseases12110288 · Cited by 8
Paggers, L., Mesotten, D., & Stragier, H. (2024) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000002103 · Cited by 8
Soliman, A. R., Saleem, H. M. E., Meligi, A. A. H. E., Naguib, M., Mohamed, R. S., Abdelaziz, G. R., Rakha, M., Abdelghaffar, S., Hamed, A. E., Hammad, H., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01564-w · Cited by 10
Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis
Takawy, M., & Abdelmalek, M. F. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01579-1 · Cited by 14
Schonfeld, E. A., Kierans, A. S., Fox, R. K., & Brandman, D. (2025) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2024.12.014 · Cited by 8
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Gene-based therapies for steatotic liver disease
Iakovleva, V., & de Jong, Y. P. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.024 · Cited by 9
The Roles of T Cells in the Development of Metabolic Dysfunction‐Associated Steatohepatitis
Ge, Z., Wu, Q., Lv, C., & He, Q. (2025) · Immunology · doi:10.1111/imm.13943 · Cited by 8
Lizcano, F., Sanabria, D., & Aviles, E. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1622186 · Cited by 9
Schiavo, L., Santella, B., Mingo, M., Rossetti, G., Orio, M., & Pilone, V. (2025) · Nutrients · doi:10.3390/nu17152409 · Cited by 14
Lee, B. K., Ghumman, U., Pedicone, L. D., Gómez-Aldana, A., & Lawitz, E. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0337 · Cited by 11
Self-citationEfficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare
Bhat, S., Fernandez, C. J., Lakshmi, V., & Pappachan, J. M. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i8.107991 · Cited by 9
Abaalkhail, F. A., Sanai, F. M., Alswat, K., Alzanbagi, A., Al-Jedai, A. H., Alshehri, A., Alfadda, A. A., Alghamdi, H., Almadi, M. A., AlEissa, M., et al. (2025) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_199_25 · Cited by 12
Ndaa, M., Pandya, P., Swensson, J., Samala, N. R., Ajaz, S., Joshi, D., Ayoub, W. S., & Akisik, F. M. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.09.205 · Cited by 12
Li, M., Hu, J., Chin, Y. H., Chew, H. S. J., & Wang, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1681965 · Cited by 9
Banerjee, M., Pal, R., & Pal, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70187 · Cited by 9
Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease
Mandorfer, M., Semmler, G., Aigner, E. S., Bräuer, A., Brix, J. M., Clodi, M., Datz, C., Effenberger, M., Felsenreich, D. M., Ludvik, B. H., et al. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02617-4 · Cited by 8
Windell, D., Magness, A. J., Beyer, C., Thomaides-Brears, H. B., Larkin, S. J., Hobson, K., Aljabar, P., Fleming, K., Fryer, E., Kendall, T. J., et al. (2025) · Journal of Clinical Pathology · doi:10.1136/jcp-2025-210311 · Cited by 9
Borges, R. D. S., de Abreu, E. S., Berton, G. G., de Paula, L. H., Conegundes, A. F., Martins, J. M. B., Martins, M. A. B., Dahbour, A., Fernandes, M. V., & Abdelmalek, M. F. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101708 · Cited by 14
Tincopa, M. A., Speliotes, E. K., Valenti, L. V. C., & Loomba, R. S. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-050324-124753 · Cited by 8
Self-citationTamaki, N., Kimura, T., Wakabayashi, S., Yamazaki, T., Iwadare, T., Tanaka, N., & Kurosaki, M. (2026) · Japanese Journal of Radiology · doi:10.1007/s11604-025-01930-2 · Cited by 11
Tsakiridis, E. E., & Steinberg, G. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70624 · Cited by 9
Li, F., Li, H., Juramt, D., Kou, K., Tacke, F., & Chen, L. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002343 · Cited by 10
Yan, R., Liu, L., Tzoulaki, I., Fan, J.-G., Targher, G., Yuan, Z., & Zhao, J. (2024) · Liver International · doi:10.1111/liv.16150 · Cited by 11
Is cardiovascular disease in PCOS driven by MASLD?
Chen, H., Simons, P. I. H. G., & Brouwers, M. C. G. J. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.10.005 · Cited by 8
Kaya, E., Syn, W., & Manka, P. P. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001083 · Cited by 7
Kaya, E., Yilmaz, Y., & Alkhouri, N. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002150 · Cited by 10
Kamrul-Hasan, A. B. M., Pappachan, J. M., Dutta, D., Nagendra, L., Kuchay, M. S., & Kapoor, N. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.101731 · Cited by 8
Role of Alcohol in Steatotic Liver Disease: Impact on Patients with Cardiometabolic Risk Factors
Capinha, F., Carvalhana, S. C., & Cortez‐Pinto, H. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08912-4 · Cited by 7
Guía de práctica clínica multidisciplinar de manejo de la esteatosis hepática metabólica
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502442 · Cited by 9
Bai, J., Yang, Z., Wang, P., Qian, B., Jiang, Z., Xu, T., Pu, H., Ye, M., Du, Y., & Fu, W. (2025) · Food & Function · doi:10.1039/d5fo01024a · Cited by 6
Thyroid Hormone Analogs: Recent Developments
Freund, M., van Geest, F. S., Groeneweg, S., van Geest, F. S., & Visser, W. E. (2025) · Thyroid · doi:10.1089/thy.2025.0245 · Cited by 8
Ashi, S. I. A., Shah, R., Iftikhar, N., Lingvay, I., Kinaan, M., & Mansi, I. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16657 · Cited by 6
Fiorucci, S., & Urbani, G. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2546812 · Cited by 10
Olveira, A., Crespo, J., Ibáñez, L., Gallego‐Durán, R., Calleja, J. L., Aller, R., Sòria, A., Gómez‐Camarero, J., Martín‐Mateos, R., Benlloch, S., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.08.023 · Cited by 10
Park, C., Kim, Y., Raygani, S., & Grunvald, E. L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630199 · Cited by 7
Pharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 33
Cerchi, E., Santo, P. A. D. E., de Oliveira, M. C., Janovsky, C. C. P. S., & Halpern, B. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01920-4 · Cited by 9
Boutari, C., Hill, M. A., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156397 · Cited by 7
Silverii, G. A., Monami, M., Rotella, F., Luca, M. D., Viozzi, T., Barazzoni, R., Buscemi, S., Busetto, L., Sbraccia, P., & Mannucci, E. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70202 · Cited by 6
Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence
Dong, W., Zhang, H., Mu, S., Shi, S., Zhang, J., & Xu, K. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70131 · Cited by 7
Holleboom, A. G., Francque, S., Cusi, K. J., & Caussy, C. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100424 · Cited by 11
Current treatment for diabetes: a holistic approach
Mourelatou, N. G., Kounatidis, D. C., Vallianou, N. G., Daniele, G., Dardano, A., & Rebelos, E. (2025) · HORMONES · doi:10.1007/s42000-025-00734-3 · Cited by 8
Beyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide
Rzepiński, Ł., Tywoniuk, A., Jaraczewska, J., Al-Shaer, A., & Wiciński, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412028 · Cited by 8
The evolving role of metabolic and bariatric surgery in contemporary clinical practice
Panichella, G., Gentile, F., Nannipieri, M., & Emdin, M. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf787 · Cited by 6
Bril, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70553 · Cited by 7
Roeb, E., Canbay, A. E., Bantel, H., Geier, A., Hofmann, W. P., Roden, M., Schattenberg, J. M., Stefan, N., Tacke, F., für die Autoren des DGVS Leitlinienkomitees/for the authors of the DGVS guideline committee, et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2769-2397 · Cited by 6
Akuta, N., Kogiso, T., Ikejima, K., Otsuka, M., Kawaguchi, T., Kawanaka, M., Takahashi, H., Tamaki, N., Nakagawa, H., 疋田隼人, et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02408-2 · Cited by 10
Self-citationEASL position paper on preclinical models of steatotic liver disease
Gallage, S., Castro, R. E., Estall, J. L., Tabas, I. A., Anstee, Q. M., TINIAKOS, D. G., Szabó, G., Yu, J., Desdouets, C., Tacke, F., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.04.029 · Cited by 8
Zambrano-Villacres, R., Campuzano-Donoso, M., Reytor-González, C., Rossetti, G., Cobellis, L., Cobellis, F., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Nutrients · doi:10.3390/nu18111751 · Cited by 9
A primer on the pleiotropic endocrine fibroblast growth factor FGF19/FGF15
Bouju, A., Nusse, R., & Wu, P. V. (2024) · Differentiation · doi:10.1016/j.diff.2024.100816 · Cited by 10
Wentworth, B. J. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.45 · Cited by 8
de Souza, M. H. G., Amaral, M. J. M., Lima, L. C. V., & Villela‐Nogueira, C. A. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18498 · Cited by 6
Medical Management of Obesity: Current Trends and Future Perspectives
Calderón, A., Aguilera-Astudillo, M., Rojas, A. P., Dowlatshahi, S., Kansara, A., Shakil, J., & Patham, B. (2025) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1503 · Cited by 8
Elangovan, H., Gunton, J. E., Zheng, M., Fan, J.-G., Goh, G. B., Grønbæk, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10795-6 · Cited by 7
Rangraze, I. R., Patoulias, D., Karakasis, P., El‐Tanani, M., & Rizzo, M. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2408753 · Cited by 8
Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease
Muzurović, E. M., Haluzík, M., Horváth, L., Vlacho, B., & Mauricio, D. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128378484250619080753 · Cited by 5
Gries, J. J., Chen, B., Bansal, M. B., Rodríguez, M., Alqahtani, S. A., Brennan, P., Lang, C. C., Tang, W. H. W., Lazarus, J. V., & Krittanawong, C. (2025) · Communications Medicine · doi:10.1038/s43856-025-00951-2 · Cited by 8
Alqatari, S. G., Alwaheed, A., Hasan, M. A., Argan, R. A., Alabdullah, M. M., & Shubbar, M. D. A. (2025) · Medicina · doi:10.3390/medicina61071292 · Cited by 11
Güldan, M., Özbek, L., Abdel‐Rahman, S. M., Narin, A. E., Orak, H. İ., Goren, H. K., Afşar, B., Rossing, P. R., & Kanbay, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70019 · Cited by 7
Weight management treatment in obesity
Rubio, M. Á., & Carreiro, S. M. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107152 · Cited by 7
Castañé, H., Jiménez-Franco, A., Onoiu, A.-I., Cambra-Cortés, V., Hernández‐Aguilera, A., Parada, D., Riu, F., Zorzano, A., Camps, J., & Joven, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178510 · Cited by 8
Wang, Y., & Wan, S. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117423 · Cited by 7
Choi, H.-I., Jeong, H. C., Jeong, J., Lee, J., Kim, D. H., Ko, K., Chae, Y., & Lee, K. (2025) · Journal of Chromatography B · doi:10.1016/j.jchromb.2025.124836 · Cited by 7
Drexel, H., Festa, A., Schmidt, T. A., Rocca, B., Dobrev, D., Agewall, S., Tamargo, J. L., & Kaser, S. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf076 · Cited by 7
Review Article: The Evolving Role of GLP ‐1 Receptor Agonists in Gastroenterology Practice
Pomenti, S. F., Gerber, A. R., Katzka, D. A., Camilleri, M., & Hur, C. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70450 · Cited by 9
Li, D., & Zhang, X. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000846 · Cited by 10
Activating protein kinases to treat diseases: Current understanding and future challenges
Jin, P., Liao, M., Liu, H., Huang, K., Fu, L., & Jin, X. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.12.004 · Cited by 7
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100686 · Cited by 7
Llach, J., Sòria, A., Graupera, I., & Cardenas, A. (2026) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2026.2632873 · Cited by 5
Ghodrati, F., Zhang, A. B., & Mahmud, N. (2026) · Gastroenterology report · doi:10.1093/gastro/goag006 · Cited by 6
Monami, M., Belluzzi, A., Buscemi, S., Busetto, L., Cohen, R., Luca, M. D., Galli, A., Mannucci, E., Petry, T. B. Z., Ragghianti, B., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70617 · Cited by 10
Lian, J., Lareu, R. R., Patil, M., & Falasca, M. (2026) · Liver International · doi:10.1111/liv.70576 · Cited by 6
Reinson, T., Bilson, J., Childs, C. E., Buchanan, R. M., Targher, G., & Byrne, C. D. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002038 · Cited by 12
Liu, M., Ma, Y., Cheang, W. S., Su, Z., & Xu, S. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.011 · Cited by 11
CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum
Schnell, O., Agarwal, A., Azizi, M., Ballwieser, D. A., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Bugianesi, E., Cebrián, A., Ceriello, A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03140-0 · Cited by 6
Self-citationInterventions for the prevention and management of cardiometabolic multiple long-term conditions
Valabhji, J., Hope, D. C. D., SAYED, N. A. E., Godia, P., Lawson, C. A., Seidu, S., & Khunti, K. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00608-2 · Cited by 6
Fomin, M., Zapf, K., Schieffer, E., Freitag, J., Bange, G., & Schieffer, B. (2026) · Inflammation Research · doi:10.1007/s00011-026-02283-w · Cited by 6
Hu, Y., Lin, C., Zhang, L., Jiang, X., Li, H., & Wu, Y. (2026) · Advanced Science · doi:10.1002/advs.202523582 · Cited by 7
Epicardial and liver fat implications in albuminuria: a retrospective study
Perdomo, C. M., Martín‐Calvo, N., Ezponda, A., Mendoza, F. J., Bastarrika, G., García-Fernández, N., Herrero, J. I., Colina, I., Escalada, J., & Frühbeck, G. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02399-5 · Cited by 6
Bae, J. H., & Cho, Y. M. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14336 · Cited by 5
Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction
Kaya, E., Yilmaz, Y., & Alkhouri, N. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2441865 · Cited by 8
Koullias, E., Papavdi, M., Koskinas, J. S., Deutsch, M. J., & Thanopoulou, A. C. (2025) · Cureus · doi:10.7759/cureus.76716 · Cited by 13
Xu, Q., Cao, Z., Yan, H., Xu, L.-L., Liu, Y., Cai, X., & Zheng, Y.-Y. (2025) · ACS Applied Materials and Interfaces · doi:10.1021/acsami.5c10593 · Cited by 7
Lonardo, A., & Weiskirchen, R. (2025) · Exploration of Drug Science · doi:10.37349/eds.2025.1008128 · Cited by 7
Oe, Y., Omori, T., Aimono, E., Furukawa, S., Kitakawa, H., Tateno, M., Sakai, K., & Cho, K. Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1501984 · Cited by 5
Wilson, M. P., Tang, A., Low, G., Zhang, L. X., Costa, A. F., Pang, E., Chang, S. D., Medellin, A., Shaheen, A. A., Dana, J., et al. (2025) · Canadian Association of Radiologists Journal · doi:10.1177/08465371251357444 · Cited by 7
Srivastava, G., Campbell, S. L., Hill, C. R., Stanley, T. L., Lawson, E. A., Apovian, C. M., Almandoz, J. P., Leggio, L., Lakdawalla, D. N., Dar, M., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.06.015 · Cited by 5
Williams, D. M., Ali, J., Cragg, J., Ch’ng, C. L., Williams, N. W., Stephens, J. W., & Min, T. (2024) · Cureus · doi:10.7759/cureus.75993 · Cited by 5
Bloom, B. E., Bragg, M. A., Jay, M. R., Harel, D., Cline, C., Crowe, M., Montoya, A., Muthuramalingam, S., Santana, R., & Albert, S. L. (2025) · Journal of Medical Internet Research · doi:10.2196/66400 · Cited by 6
New Names, New Drugs, Better Outcomes in Steatotic Liver Disease
Peverelle, M., Mbelle, M., & Joshi, D. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0655 · Cited by 4
Kumar, A. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.1058 · Cited by 7
Bharaj, I. S., Purewal, K., Munaim, J., Brar, A. S., Kacheria, A., Simister, A., Thirupathy, U., Gupta, P., Kahlon, J., Thwe, E. E., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13092192 · Cited by 7
The role of hypothalamus in the pathophysiological process of MASLD and advances in drug discovery
Wei, S., Dong, Y., Wang, Y., Li, G., Zhao, Y., & Zheng, R. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107972 · Cited by 5
Barazzoni, R., Monami, M., Buscemi, S., Busetto, L., Luca, M. D., Navarra, G., Ragghianti, B., Silverii, G. A., Belluzzi, A., Mannucci, E., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70204 · Cited by 6
Fragozo-Ramos, M. C., Schenker, G., Hepprich, M., Gallo‐Villegas, J., Züger, T., & Garcia‐Tirado, J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0335060 · Cited by 6
Quantitative Approaches to Accelerate MASH Drug Discovery and Development
Abouelhassan, Y., Tallapaka, S. B., Mehrani, R., Siler, S. Q., Li, Q., Wang, Z., & Trujillo, M. E. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70103 · Cited by 5
Elangovan, H., Loomba, R. S., Muthiah, M. D., Schattenberg, J. M., Zheng, M., Noureddin, M., Mantzoros, C. S., & George, J. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0857 · Cited by 5
Self-citationDadey, E., Lim, T., & Makaronidis, J. (2025) · Clinical Medicine · doi:10.1016/j.clinme.2025.100528 · Cited by 5
Metadata
- Authors
- Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., Brouwers, B., Robins, D. A., Nikooie, A., Bunck, M. C., Haupt, A., & Sanyal, A. J.
- Affiliations
- University of California San Diego (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-25
- Volume
- 391
- Issue
- 4
- Pages
- 299-310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399461049
- Cited by
- 1,005
- References
- 37
- Citations by year
- 2026: 458 · 2025: 433 · 2024: 114
- FWCI
- 306.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, nonalcoholic steatohepatitis, liver fibrosis, GIP/GLP-1 receptor agonist, fibrosis regression, dose-response relationship, liver biopsy, non-alcoholic fatty liver disease, obesity, type 2 diabetes, weight loss, drug safety, adverse events, liver complications, hepatocellular carcinoma, liver cirrhosis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Fatty Liver, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.